In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sandoz International GmbH

www.sandoz.com

Latest From Sandoz International GmbH

Sandoz Seeks Review Of Enbrel Ruling

Sandoz is seeking an en banc rehearing of a recent appeals court decision that stands to keep its Erelzi biosimilar etanercept rival to Enbrel off the market until 2029 in the US, claiming that the ruling provides a “playbook” for originators to extend patents beyond their legitimate terms.

Legal Issues Intellectual Property

Sandoz Strikes €150m Deal On Antibiotics In Austria

Sandoz has announced joint plans with the Austrian government to invest over €150m in antibiotics manufacturing.

Deals Manufacturing

Sandoz Unveils Zero-Profit COVID-19 Portfolio

Lutz Hegemann, chief operating officer for global health at Novartis, says the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.

Coronavirus COVID-19 Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register